North America Diabetic Retinopathy Market Size & Outlook, 2025-2033
North America Diabetic Retinopathy Market Insights
- As per Reed Intelligence insights, North America’s Diabetic Retinopathy Market was valued at USD 3372.62 Million in 2024 and is anticipated to expand to USD 6482.57 Million by 2033.
- From 2026 to 2033, the market is anticipated to expand at a CAGR of 7.46%.
- Within By Type, Proliferative Diabetic Retinopathy accounted for the largest market size in 2024.
- During the forecast period, Proliferative Diabetic Retinopathy is anticipated to remain the highest-growth segment within the By Type category.
![North America Diabetic Retinopathy Market Size, Share & Growth Analysis By [2033]](https://reedintelligence.com/uploads/charts/diabetic-retinopathy-market-north-america--35514.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2024, North America contributed 36.94% to the overall global Diabetic Retinopathy Market size.
- By 2033, United States is anticipated to dominate the global market based on market size.
- Canada is expected to witness the fastest growth within North America, attaining USD 1915.73 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 3372.62 Million |
| Market Size In 2033 | USD 6482.57 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 7.46% (2025-2033) |
| Segmnetation Covered | |
| North America |
|
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
North America Diabetic Retinopathy Market Country 2025-2033 (USD Million)
| North America | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | XX.x | XX.x | XX.x | 2389.16 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Canada | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 2109.91 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 1352.76 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
